
Sign up to save your podcasts
Or


H5N1 avian influenza is back in the headlines, and on two fronts at once. Florian Krammer starts with the basics: why the subtype is named after its two spike proteins, hemagglutinin and neuraminidase, what separates highly pathogenic from low pathogenic strains, and why the virus still does not spread from human to human. The answer lies in the receptors, since avian strains bind alpha-2,3-linked sialic acid, which in humans is found deep in the lung but not in the upper respiratory tract. Since 1997 there have been around 900 human cases, roughly half of them fatal. Since 2020 the clade 2.3.4.4b variant has spread worldwide and shows a striking tendency to infect mammals. In 2024 it turned up unexpectedly in US dairy cattle, where it replicates in the mammary glands and spreads between cows through unsanitized milking equipment. An active outbreak in Washington State's Yakima Valley has now caused three human infections, one of them fatal, and a farm worker union reports further cases among people who avoid testing out of fear of immigration enforcement. On top of that, a mink farm outbreak in Utah has been running uncontrolled since August. The core concern: if someone is infected with seasonal flu and H5N1 at the same time, the viruses can swap genomic segments. That is exactly how the last influenza pandemics began.
Report about the cattle outbreak in Washington State:
Detailed report about the mink outbreak in Utah:
Farm Workers Union statement about human H5N1 infections on Twitter:
+++++
You can support the podcast via our German Steady page:
Questions, feedback or topic suggestions?
+++++
Krammer laboratory information
Krammer Laboratory at the Icahn School of Medicine at Mount Sinai
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness
Ignaz Semmelweis Institute
+++++
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.
I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).
My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.
My work on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.
My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
Recorded in Seoul, this episode is about Hantaan virus, the prototype hantavirus that gave the whole group its name. Florian Krammer explains how the disease first appeared during the Korean War in more than 3,000 soldiers, how virologist Ho-Wang Lee traced it to the striped field mouse in 1976 and isolated the virus two years later, and why the Hantan River is spelled with one A while the virus has two. The illness is known as Korean hemorrhagic fever with renal syndrome: after an incubation period of usually twelve to sixteen days come flu-like symptoms, a hypotensive phase, and a renal phase that often requires dialysis. The case fatality rate is around six percent today, with China reporting 9,000 to 12,000 cases a year and South Korea 400 to 600. The episode also covers Seoul virus, discovered by the same researcher in 1980: carried by Norway rats, it has spread worldwide with them and was found in about ten percent of rats sampled in New York City. Pet rats deserve particular attention after an outbreak across the US and Canada in 2016 and 2017.
Overview of hemorrhagic fever with renal syndrome in Asia: https://pmc.ncbi.nlm.nih.gov/articles/PMC9966805/
Review about Seoulvirus in rats: https://pmc.ncbi.nlm.nih.gov/articles/PMC6669632/
Report about 2017 Seoulvirus outbreak in the US: https://pmc.ncbi.nlm.nih.gov/articles/PMC5794350/
+++++
You can support the podcast via our German Steady page:
Questions, feedback or topic suggestions?
+++++
Krammer laboratory information
Krammer Laboratory at the Icahn School of Medicine at Mount Sinai
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness
Ignaz Semmelweis Institute
+++++
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.
I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).
My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.
My work on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.
My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
For Halloween, this episode is about one of the scariest viruses around, at least if you’re an insect: the baculovirus. Florian Krammer explains how these large DNA viruses infect the caterpillars of moths and butterflies, change their behavior so they climb to the top of the plant, and then liquefy them so the virus spreads as widely as possible. Two forms of the virus make this possible: one that spreads within the insect and a highly stable form encased in protein crystals that can survive in the soil for years to decades. Because each baculovirus infects only one insect species, they have been used as targeted biopesticides since the 1940s, for example against the codling moth or the gypsy moth. Since the 1990s, they have also become a key biotechnology tool for producing proteins in insect cells, including for the HPV vaccine Cervarix, the flu vaccine Flublok and the Novavax COVID-19 vaccine. Recorded in Chile just before the International Hantavirus Conference.
Baculovirus review article: https://www.ncbi.nlm.nih.gov/books/NBK543465/
Overview article about baculoviruses as pest control: https://biocommunication.org/en/insects360/insects-vs-plants/baculoviruses-a-natural-and-sustainable-solution-for-pest-control/
+++++
You can support the podcast via our German Steady page:
Questions, feedback or topic suggestions?
+++++
Krammer laboratory information
Krammer Laboratory at the Icahn School of Medicine at Mount Sinai
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness
Ignaz Semmelweis Institute
+++++
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.
I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).
My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.
My work on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.
My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
Shamonda virus is a bunyavirus of the Simbu serogroup, closely related to Schmallenberg, Akabane and Oropouche virus. It was first identified in 1965 in Ibadan, Nigeria, and is known to infect cattle, sheep and goats, transmitted by biting midges. In summer 2026, it caused outbreaks in cattle in Switzerland, Germany, Austria and several other European countries, and two new variants were identified. In October, a person in France became the first known human fatality: a severely immunocompromised patient after a stem cell transplant, in whom metagenomic sequencing found the virus mainly in the brain. Florian Krammer explains why the risk for healthy people is very low, comparable to Usutu virus, and why serosurveys would help clarify how often humans are exposed.
Paper describing the first (and fatal) human Shamonda virus case in France: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2026.31.42.2600883
Paper describing Shamonda virus EU1 in cattle in Germany: https://wwwnc.cdc.gov/eid/article/32/12/26-1496_article
Paper describing Shamonda virus EU2 in cattle in Germany: https://pmc.ncbi.nlm.nih.gov/articles/PMC13633466/#sec2
+++++
You can support the podcast via our German Steady page:
Questions, feedback or topic suggestions?
+++++
Krammer laboratory information
Krammer Laboratory at the Icahn School of Medicine at Mount Sinai
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness
Ignaz Semmelweis Institute
+++++
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.
I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).
My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.
My work on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.
My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
With the respiratory virus season starting, Florian Krammer gives an overview of what’s circulating and how to protect yourself. He explains why respiratory viruses spread more easily in the cold and how influenza plays ping pong between the northern and southern hemispheres. The focus is on the three viruses we have good countermeasures for. For SARS-CoV-2, the share of severe infections has been falling steadily since 2022, last year’s vaccines reached an effectiveness of 50 to 60 percent, and new options like the Spanish protein vaccine Bimervax and a combined COVID and flu mRNA vaccine are now available in Europe. Influenza causes 3 to 5 million severe cases and up to 650,000 deaths worldwide every year. An early H1N1 rise closely matches this year’s vaccine strain, and an mRNA flu vaccine has now been licensed in the US. For RSV, there are vaccines for adults over 60, maternal vaccination to protect newborns, and a monoclonal antibody for babies. Plus: why N95 masks and antivirals like Paxlovid, taken early, are useful additions.
SARS-CoV-2 variant data from the US CDC: https://www.cdc.gov/covid/php/variants/variants-and-genomic-surveillance.html
Influenza surveillance data from the US CDC: https://www.cdc.gov/fluview/
+++++
You can support the podcast via our German Steady page:
Questions, feedback or topic suggestions?
+++++
Krammer laboratory information
Krammer Laboratory at the Icahn School of Medicine at Mount Sinai
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness
Ignaz Semmelweis Institute
+++++
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.
I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).
My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.
My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.
My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
Lymphocytic choriomeningitis virus (LCMV) is an arenavirus closely related to Lassa virus, but unlike Junin virus it isn’t limited to South America: it’s found worldwide in house mice. Florian Krammer explains how people get infected, mostly by inhaling dust from dried mouse urine, droppings or saliva, and less often through bites, contaminated food or infected pets like hamsters. Most infections go unnoticed, and studies from Croatia and Bratislava found antibodies in up to 40 percent of people. LCMV becomes dangerous for two groups: in organ transplant recipients it resembles a hemorrhagic fever with a fatality rate above 70 percent, and in pregnant women it can cause miscarriage or severe birth defects. There is no vaccine and no effective treatment. On the bright side, research with LCMV in mice revealed how T cells recognize infected cells, earning Rolf Zinkernagel and Peter Doherty the 1996 Nobel Prize.
Recent review about LCMV: https://pmc.ncbi.nlm.nih.gov/articles/PMC8163193/
+++++
You can support the podcast via our German Steady page:
Questions, feedback or topic suggestions?
+++++
Krammer laboratory information
Krammer Laboratory at the Icahn School of Medicine at Mount Sinai
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness
Ignaz Semmelweis Institute
+++++
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.
I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).
My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.
My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.
My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
Since the 1970s, cats in Sweden, and later in and around Vienna, have been falling ill with a mysterious brain inflammation known as staggering disease. Affected cats develop fever, behavioral changes, a staggering gait and often paralysis of the hind legs, and most have to be euthanized. For decades Borna disease virus was the main suspect, but metagenomics finally solved the case: in 2023, rustrela virus, a close relative of rubella virus, was detected in 27 out of 29 affected cats from Sweden, Germany and Austria. Florian Krammer explains how cats catch the virus from the mice they hunt, why different mouse species carry it in Germany and Sweden, and why it has now also turned up in a mountain lion in Colorado. There is no vaccine and no treatment, and no human cases have been reported. He also introduces ViroKitty, a citizen science project in Vienna where cat owners can hand over their outdoor cats' prey for virus research.
Video of mountain lion in Colorado with staggering disease/rustrelavirus infection: https://www.youtube.com/watch?v=KtofjO4Tfds
+++++
You can support the podcast via our German Steady page:
Questions, feedback or topic suggestions?
+++++
Krammer laboratory information
Krammer Laboratory at the Icahn School of Medicine at Mount Sinai
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness
Ignaz Semmelweis Institute
+++++
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.
I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).
My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.
My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.
My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
Junin virus causes Argentine hemorrhagic fever, a disease with a case fatality rate of 20 to 30 percent. Florian Krammer explains why these New World arenaviruses are named after sand (they package host cell ribosomes that look like grains of sand under the electron microscope) and what makes their spike protein unusual: the signal peptide stays part of the glycoprotein complex, something found nowhere else in biology. The virus is carried by field mice, mainly the dryland vesper mouse, and people usually get infected by inhaling dust from dried urine and feces. That's why it mostly affects men working in agriculture, with over 90 percent of the 300 to 500 annual cases occurring in rural areas. Unlike most hemorrhagic fevers, this one has countermeasures: the live attenuated vaccine Candid One with 95 percent efficacy, and convalescent plasma that cuts fatality to one or two percent but causes late neurological symptoms in about 8 to 10 percent of patients. Florian Krammer's own lab is about to publish monoclonal antibodies that could replace plasma therapy.
Information about Junin virus and Argentine hemorrhagic fever from the UK Health Security Agency: https://www.gov.uk/guidance/argentine-haemorrhagic-fever-origins-reservoirs-transmission-and-guidelines
New paper about Junin virus monoclonal antibodies that could be used for treatment: https://journals.asm.org/doi/10.1128/mbio.00214-26
+++++
You can support the podcast via our German Steady page:
Questions, feedback or topic suggestions?
+++++
Krammer laboratory information
Krammer Laboratory at the Icahn School of Medicine at Mount Sinai
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness
Ignaz Semmelweis Institute
+++++
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.
I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).
My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.
My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.
My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
Human metapneumovirus (HMPV) is one of the most common respiratory viruses there is, yet few people have heard of it. Florian Krammer explains why this relative of RSV is the second most common cause of respiratory illness in children under five and is behind 8 to 15 percent of pneumonia cases in that age group. Virtually every child has been infected by age five, but immunity doesn't last, so reinfections happen throughout life. The highest risk falls on premature babies, infants between six and twelve months, adults over 65, and people with COPD, asthma or weakened immune systems. HMPV was only discovered in 2001 in Rotterdam but has likely circulated in humans for around 200 years after jumping from birds. Unlike RSV, there are no vaccines or antibody treatments yet, though combination vaccines are in clinical trials.
Human metapneumovirus information from the CDC: https://www.cdc.gov/human-metapneumovirus/about/index.html
Human metapneumovirus information from the WHO: https://www.who.int/news-room/questions-and-answers/item/human-metapneumovirus-(hmpv)-infection
+++++
You can support the podcast via our German Steady page:
Questions, feedback or topic suggestions?
+++++
Krammer laboratory information
Krammer Laboratory at the Icahn School of Medicine at Mount Sinai
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness
Ignaz Semmelweis Institute
+++++
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.
I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).
My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.
My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.
My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
The 1918 Spanish flu was the deadliest influenza pandemic on record: between 20 and 100 million people died, from a world population of just 1.8 billion at the time. Florian Krammer explains why this H1N1 virus, with a case fatality rate of two to three percent, was so dangerous, where the misleading name comes from (Spain was neutral and had a free press when warring countries did not) and why mortality peaked among 20 to 40 year olds in a distinctive W-shaped curve. He also lays out his own hypothesis: seasonal influenza may have vanished entirely between 1891 and 1918, leaving a whole generation with no immunity at all. The episode covers cytokine storms, anti-mask leagues, famous victims including Gustav Klimt and Egon Schiele, and the reconstruction of the virus from formalin-fixed pathology slides and a body exhumed from Alaskan permafrost. It closes with 2009, when a descendant of the 1918 virus jumped back out of pigs into people.
Link to John Barry’s book ‘The Great Influenza’: https://en.wikipedia.org/wiki/The_Great_Influenza
+++++
You can support the podcast via our German Steady page:
Questions, feedback or topic suggestions?
+++++
Krammer laboratory information
Krammer Laboratory at the Icahn School of Medicine at Mount Sinai
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness
Ignaz Semmelweis Institute
+++++
Conflict of interest statement
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. Mount Sinai has spun out a company, CastleVax, to commercialize NDV-based SARS-CoV-2 vaccines and I am named as co-founder and scientific advisory board member of that company.
I have previously consulted for Curevac, Merck, Gritstone, Sanofi, Seqirus, GSK and Pfizer and I am currently consulting for 3rd Rock Ventures (US) and Avimex (Mexico).
My laboratory has been collaborating in the past with Pfizer on animal models of SARS-CoV-2 and with GlaxoSmithKline and VIR on the development of influenza virus vaccines and therapeutics and we are currently collaborating with Dynavax, Inspirevax and Inimmune on development of influenza virus vaccines.
My work in the on immunity and infectious diseases in the US is supported by the National Institutes of Health, but also by FluLab and Tito’s Handmade Vodka. In the past I have also received funding from the Bill and Melinda Gates Foundation, PATH and the US Department of Defense.
My work in Austria is supported by the Ludwig Boltzmann Gesellschaft and by the Ignaz Semmelweis Institute through the Medical University of Vienna.
From the publisher's feed